The steady increase in cancer incidence rates necessitates studies of global risk factors for cancer and a search for novel methods of effective primary prevention. According to the International Cancer Research Agency (IARC, 2017), obesity also increases the risk for development of 13 most common malignant neoplasms (MNs), including breast, colon, pancreas, bladder, and endometrial cancers; the incidence of MNs caused by overweight and obesity among women is 5.4%. Menopausal metabolic syndrome (metabolic syndrome associated with the development of hypogonadism) occurs in 40% of postmenopausal women. Menopausal hormone therapy (MHT) for women in the early postmenopause and/or those who are younger than 60 years, and overweight control reduces overall mortality from 30 to 52% and contributes to the primary prevention of a number of MNs, including breast cancer, type 2 diabetes mellitus, and cardiovascular disease. In addition to MHT, lifestyle modification should be recommended to control body weight and to in
Translated title of the contributionMenopause, obesity, and comorbidity: Possibilities of menopausal hormone therapy
Original languageRussian
Pages (from-to)43-48
Number of pages6
JournalAkusherstvo i Ginekologiya (Russian Federation)
Volume2019
Issue number5
DOIs
StatePublished - 2019

    Scopus subject areas

  • Obstetrics and Gynecology

    Research areas

  • breast cancer, menopausal hormone therapy, menopause, metabolic syndrome, obesity, МГТ, менопауза, метаболический синдром, ожирение, рак молочной железы

ID: 76490548